无容量
医学
封锁
CD8型
彭布罗利珠单抗
无进展生存期
PD-L1
肺癌
内科学
肿瘤微环境
肿瘤科
免疫系统
细胞毒性T细胞
肿瘤浸润淋巴细胞
免疫检查点
免疫疗法
癌症研究
癌症
免疫学
受体
化疗
生物
生物化学
体外
作者
Yukiko Shimoda,Ryota Shibaki,Tatsuya Yoshida,Shuji Murakami,Masayuki Shirasawa,Masahiro Torasawa,Yuji Matsumoto,Ken Masuda,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Yuichiro Ohe,Noriko Motoi
标识
DOI:10.1016/j.cllc.2022.04.001
摘要
The effectiveness of PD-1 blockade therapy in advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is limited. We investigated whether patient characteristics, PD-L1 expression, and immune cell (IC) status in the tumor microenvironment (TME) were associated with PD-1 blockade therapy outcomes.We retrospectively reviewed patients with advanced EGFR-mutant NSCLC treated with PD-1 blockade (nivolumab or pembrolizumab) between January 2016 and March 2018. The PD-L1 expression tumor proportion score (TPS) and types and distribution of ICs (CD8, PD-1, CD204, tumoral, and stromal) in the TME were analyzed.Among 57 EGFR-mutant NSCLC patients treated with PD-1 blockade, 39 patients had sufficient tissues for analyzing the TME. The overall response rate (ORR) of PD-1 blockade was 12.3%. Only tumoral CD8 positive (CD8+) IC status was significantly associated with the response (median tumoral CD8+ICs: 299/mm2 vs. 115/mm2, P < .01). Among the 6 patients with concurrent high PD-L1 expression (TPS: ≥ 50%)/high tumoral CD8+ ICs (≥ 205/mm2), 5 (83.3%) showed a response and a significantly longer progression-free survival (PFS) (PFS: 9.4M vs. 1.8M, P < .01). In contrast, none of the 7 patients with high PD-L1 expression/low tumoral CD8+ICs (<205/mm2) showed a response.Concurrent high PD-L1 expression and high tumoral CD8+ ICs could predict the response and longer PFS of PD-1 blockade therapy in EGFR-mutant patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI